Fowler Christopher J
Department of Pharmacology and Clinical Neuroscience, Umeå University, SE901 87 Umeå, Sweden.
Fundam Clin Pharmacol. 2006 Dec;20(6):549-62. doi: 10.1111/j.1472-8206.2006.00442.x.
Although cannabis has been used both recreationally and for medicinal purposes since ancient times, it was not until the 1990s that the receptors responsible for many of the actions of Delta(9)-tetrahydrocannabinol, the main psychoactive ingredient of cannabis, were cloned. Since then, our knowledge of the endogenous cannabinoid system, its physiology, pharmacology and therapeutic potential have expanded enormously. In the present review, the cannabinoid system is described, with particular emphasis on the mechanisms of removal and metabolism of the endocannabinoid signalling molecule anandamide. The current literature shows that cells can accumulate anandamide, and that this process can be disrupted pharmacologically, but that the nature of the mechanism(s) involved remains a matter of some debate. The main enzyme for the hydrolysis of anandamide, fatty acid amide hydrolase, is well characterized, and molecules selectively inhibiting this enzyme have potential therapeutic utility in a number of areas, in particular for the treatment of pain conditions.
尽管大麻自古以来就被用于娱乐和医疗目的,但直到20世纪90年代,负责大麻主要精神活性成分Δ⁹-四氢大麻酚许多作用的受体才被克隆出来。从那时起,我们对内源性大麻素系统及其生理学、药理学和治疗潜力的了解有了极大的扩展。在本综述中,对大麻素系统进行了描述,特别强调了内源性大麻素信号分子花生四烯乙醇胺的清除和代谢机制。当前的文献表明,细胞可以积累花生四烯乙醇胺,并且这个过程可以被药物学方法破坏,但所涉及机制的本质仍存在一些争议。花生四烯乙醇胺水解的主要酶——脂肪酸酰胺水解酶,已得到充分表征,选择性抑制该酶的分子在许多领域具有潜在的治疗用途,特别是在疼痛病症的治疗方面。